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Few data are available regarding the use of antithrombotic strategies in coronary artery dis-
ease patients with atrial fibrillation (AF) in everyday practice. We sought to describe the
prevalence of AF and its antithrombotic management in a contemporary population of pa-
tients with stable coronary artery disease.
Methods and Findings
CLARIFY is an international, prospective, longitudinal registry of outpatients with stable cor-
onary artery disease, defined as prior (12 months) myocardial infarction, revascularization
procedure, coronary stenosis >50%, or chest pain associated with evidence of myocardial
ischemia. Overall, 33,428 patients were screened, of whom 32,954 had data available for
analysis at baseline; of these 2,229 (6.7%) had a history of AF. Median (interquartile range)
CHA2DS2-VASc score was 4 (3, 5). Oral anticoagulation alone was used in 25.7%, anti-
platelet therapy alone in 52.8% (single 41.8%, dual 11.0%), and both in 21.5%. OAC use
was independently associated with permanent AF (p<0.001), CHA2DS2-VASc score
(p=0.006), pacemaker (p<0.001), stroke (p=0.04), absence of angina (p=0.004), decreased
left ventricular ejection fraction (p<0.001), increased waist circumference (p=0.005), and
longer history of coronary artery disease (p=0.008). History of percutaneous coronary inter-
vention (p=0.004) and no/partial reimbursement for cardiovascular medication (p=0.01,
p<0.001, respectively) were associated with reduced oral anticoagulant use.
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Conclusions
In this contemporary cohort of patients with stable coronary artery disease and AF, most of
whom are theoretical candidates for anticoagulation, oral anticoagulants were used in only
47.2%. Half of the patients received antiplatelet therapy alone and one-fifth received both
antiplatelets and oral anticoagulants. Efforts are needed to improve adherence to guidelines
in these patients.
Trial Registration
ISRCTN registry of clinical trials: ISRCTN43070564.
Introduction
Patients with coronary artery disease (CAD) generally receive antiplatelet therapy, while pa-
tients with atrial fibrillation (AF) may require oral anticoagulants (OACs) to reduce the risk of
thromboembolic events [1,2]. European guidelines on AF have extended indications for antic-
oagulation for eligible patients at risk of stroke [1]. About 6% of all CAD patients have associat-
ed AF, and among AF patients, 20–30% have associated CAD, some of who undergo
percutaneous coronary interventions (PCIs) with stent implantation [1–3]. After implantation,
the rate of stent thrombosis is high in the absence of antiplatelets [2]; current guidelines there-
fore recommend the use of an aspirin—P2Y12-receptor inhibitor combination therapy for 1–12
months afterwards, and for 1 year in all patients after an acute coronary syndrome (ACS) [1,2].
In subjects with stable CAD and AF, where there is most often the requirement for long-term
OAC, there is the need to balance the risk of stroke, coronary events, and recurrent cardiac is-
chemia against the harm of bleeding caused by combining OAC and antiplatelets [3]. The goal
of this analysis from the CLARIFY registry was to describe the prevalence of AF and its antith-
rombotic management in a contemporary population of patients with stable CAD, overall and
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CLARIFY is an international, prospective, longitudinal registry of outpatients with stable
CAD; 33,428 patients from 45 countries were screened (November 2009 to July 2010) of whom
32,954 had data available for analysis [4]. Eligible patients were adults (18 years) with stable
CAD, defined as having any of the following criteria: either prior (>3 months) documented MI
or revascularization procedure, coronary stenosis>50% on coronary angiography, or chest
pain associated with proven myocardial ischemia proven by stress electrocardiogram, stress
echocardiography, or myocardial imaging. Patients were excluded if they had been hospitalized
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within the previous 3 months for cardiovascular disease (including for revascularization), were
to undergo planned revascularization, or were unlikely to complete 5-year follow-up. In addi-
tion, for patients with documented MI or revascularization procedure, those who had either of
these events in the year before inclusion were excluded of the analysis.
Recruitment (of 10–15 outpatients per physician) was performed by cardiologists, internists
and primary care physicians, with the aim of consecutive enrolment of eligible patients. Physi-
cian selection was based on the best available sources, either local or regional, concerning the
epidemiology and medical care data, including available market data and epidemiological sur-
veys. A general target of 25 patients/million inhabitants was used (range 12.5–50) to ensure
balanced representation of participating countries.
We focused this analysis on patients diagnosed with AF or atrial flutter associated with sta-
ble CAD. Patients with a history of myocardial infarction in the 12 months before inclusion
were excluded. AF (paroxysmal, persistent, or permanent), as identified by each investigator,
was defined on the electrocardiogram by the replacement of consistent P waves by rapid oscil-
lations or fibrillatory waves that vary in amplitude, shape, and timing, associated with an irreg-
ular, often rapid, ventricular response with atrioventricular conduction intact. Individual
patient management decisions were decided by each physician.
The CHA2DS2-VASc score was calculated retrospectively (one point each for a history of
heart failure, history of hypertension, age 65–75 years, presence of diabetes mellitus, vascular
disease [prior MI, peripheral artery disease, aortic plaque], and sex category [female]; and two
points for a prior stroke or TIA or age75 years) [5]. A modified version of the HAS-BLED
(hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile
international normalized ratio, elderly [>65], drugs/alcohol concomitantly) score, excluding
labile international normalized ratio, was calculated to assess bleeding risk, with a score3 in-
dicating high risk [6].
Investigators completed standardized electronic case report forms at baseline. Measures
were implemented to ensure data quality: onsite monitoring visits of 100% of the data in 5% of
centres selected at random over 5 years of follow-up; regular telephone contact with investiga-
tors; and centralized verification of the eCRF for completeness, consistency, and accuracy.
Data were collected on patient baseline characteristics, risk factors and lifestyle, medical histo-
ry, physical condition and vital signs, symptoms, and treatments. We analysed the CLARIFY
population by antithrombotic therapy (OAC alone or combined with antiplatelet therapy, and
one or more antiplatelet[s] without OAC).
CLARIFY is an observational registry, and the size of the population is not based on treat-
ment comparison; the number of patients in this analysis was dependent on the presence or ab-
sence of atrial fibrillation in a cohort of patients with stable CAD.
Statistical Analysis
All CLARIFY data are collected and analysed at an independent academic statistics centre, the
Robertson Centre for Biostatistics, University of Glasgow, UK. Baseline variables are summa-
rized as means (standard deviation) or medians (interquartile range) for continuous data and
as counts and percentages for categorical data, and were based on patients in whom data were
available. Comparisons between patients with OAC use and those without were made using
one-way ANOVA or the Kruskal-Wallis test for continuous variables and Pearson’s Chi-
squared test or Fisher’s exact test for categorical variables. A multivariable analysis of indepen-
dent correlates of OAC use was performed using a logistic regression model. All clinical base-
line variables, with the exception of HAS-BLED score, were considered for entry into the
model as predictors of OAC use and univariate models for each were produced. The
Atrial Fibrillation and Stable Coronary Artery Disease
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multivariable model was built using a stepwise selection method applied to the remaining sig-
nificant univariate predictors. A sensitivity analysis on the multivariable model excluding pa-
tients from East Asia was also performed to determine whether clinical differences in
guidelines for this population affected the multivariable model. All analyses were performed
using SAS version 9.2. A significance level of 0.05 was used to test for statistical differences; all
tests used were two-sided.
Results
Overall, 2,229 of 32,954 patients (6.7%) with stable CAD had a history of known AF, had data
on use of antiplatelet or OAC therapy, and had not had a myocardial infarction within the
same or previous calendar year (Fig 1). Mean age in these patients was 70 (9) years and median
CHA2DS2-VASc score was 3 (2–5). Known median duration of CAD was 8 (4–13) years and
Fig 1. Patient flow chart.
doi:10.1371/journal.pone.0125164.g001
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AF was permanent in 41.5% (n = 753). OAC alone was used in 25.7% of patients, antiplatelet
therapy alone in 52.8% (single 41.8%, dual 11.0%), and both in 21.5%; OAC was thus pre-
scribed to 47.2% of the patients with CAD and AF (Fig 2 and Table 1). Prevalence of AF associ-
ated with stable CAD was higher in Europe, North America (Canada), Republic of South
Africa, the UK, Russia and Ukraine (ranging from 8.0% to 9.1%) whilst the use of OAC ap-
peared lower in Russia and Ukraine, the Middle East, and East Asia (ranging from 24.4% to
34.2%) (Table 2).
Patient baseline characteristics by antithrombotic therapy are shown in Table 3. Non-
vitamin K antagonist OACs (dabigatran, rivaroxaban, or apixaban) were not commercially
available during the recruitment period. OAC-treated patients were older and more likely to
have permanent AF (Fig 3) or be treated with a pacemaker. Half of the patients in both groups
had a previous MI, but those on OAC had a lower rate of previous PCI and a higher rate of pre-
vious CABG. Fewer patients on OAC had anginal symptoms. The risk of stroke (CHA2DS2-
Fig 2. Antithrombotic therapy in patients with coronary artery disease and atrial fibrillation with increasing CHA2DS2-VASc score. Any antiplatelet
therapy alone (single or dual) is therefore: a 1,178 (52.8%), b 130 (69.5%), c 542 (56.4%), d 505 (46.9%). Abbreviations: AP, antiplatelet; OAC,
oral anticoagulant.
doi:10.1371/journal.pone.0125164.g002
Table 1. Use of antithrombotic strategies overall and in CHA2DS2-VASc subgroups.
Parameter Subgroup n Single AP, n (%) Dual AP, n (%) OAC alone, n (%) OAC+AP, n (%)
All patients 2,229 932 (41.8) 246 (11.0) (any antiplatelet therapy alone: 1,178 [52.8]) 572 (25.7) 479 (21.5)
CHA2DS2-VASc score
0–1 187 92 (49.2) 38 (20.3) (any antiplatelet therapy alone: 130 [69.5]) 27 (14.4) 30 (16.0)
2–3 960 439 (45.7) 103 (10.7) (any antiplatelet therapy alone: 542 [56.4]) 228 (23.8) 190 (19.8)
>3 1,076 400 (37.2) 105 (9.8) (any antiplatelet therapy alone: 505 [46.9]) 316 (29.4) 255 (23.7)
Abbreviations: AP, antiplatelet; OAC, oral anticoagulant therapy.
doi:10.1371/journal.pone.0125164.t001
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VASc score) or bleeding (HAS-BLED score) was higher in patients receiving OAC (both
p<0.001). Patients on OAC therapy had a slightly higher heart rate and lower systolic blood
pressure and a lower left ventricular ejection fraction. Patients on OAC were more likely to be
reimbursed for cardiovascular medication. Aspirin was given to 39.8% of patients on OAC and
to 90.3% of those not treated by OAC. Patients on OAC were less likely to be treated with a
thienopyridine (7.9% vs 22.0%) (Table 3).
In multivariable analysis, OAC use was independently associated with permanent AF,
CHA2DS2-VASc score, pacemaker therapy, stroke, absence of angina, decreased left ventricular
ejection fraction, increased waist circumference, and longer history of CAD (Fig 4). Conversely,
history of PCI, and no/partial reimbursement for cardiovascular medication were associated
with reduced likelihood of OAC use.
Discussion
In this contemporary international cohort of patients with stable CAD and AF, most of whom
are theoretical candidates for anticoagulation, less than 50% of patients received OACs. Half of
the patients received antiplatelet therapy alone and one-fifth received antiplatelets plus OAC.
This analysis is the first of its kind to evaluate the applicability of the AF guidelines in this sub-
group of patients with stable CAD and, to our knowledge, is the largest published dataset in
this population, in whom antithrombotic management strategies have been related to baseline
clinical characteristics [7].
Limited published evidence is available on the optimal management strategy for patients
with CAD and AF [8–13]. Our population reflects a “real-world” scenario for the applicability
of current AF guidelines. In our analysis, most of the patients had a CHA2DS2-VASc score2,
with only a minority receiving guideline-recommended antithrombotic therapy. These data
suggest under-treatment, but also possible over-treatment, with 21.5% receiving both OAC
and antiplatelet therapy, although whether there is benefit or harm in adding antiplatelet thera-
py to OAC in patients with both AF and coronary artery disease remains debatable [14].
We identified risk factors associated with lack of OAC use. Compared with previous studies
on guideline adherence in the more general setting of AF, and based on the 2010 guidelines [1],
we found that an even lower percentage of patients with stable CAD and AF was appropriately
treated [15,16]. When divided into groups at increasing risk with higher CHA2DS2-VASc
score, patients most at risk of thromboembolism were poorly treated with more OAC. In
Table 2. Geographic distribution of patients in CLARIFY and use of oral antithrombotic therapy.
Region Total population (n) AF subgroup, n (%) AF patients taking anticoagulation
(alone or with antiplatelet), n (%)
Total 32,954 2,229 1,051
Europe 15,388 1,233 (8.0) 664 (53.9)
Canada, Republic of South Africa, Australia and the UK 4,954 451 (9.1) 224 (49.7)
Russia and Ukraine 3,026 256 (8.5) 63 (24.6)
Central and South America 2,231 80 (3.6) 42 (52.5)
Middle East 1,511 38 (2.5) 13 (34.2)
East Asia 5,035 160 (3.2) 39 (24.4)
India 809 11 (1.4) 6 (54.5)
No adjustment for baseline differences in the populations from different regions.
Abbreviation: AF, atrial ﬁbrillation.
doi:10.1371/journal.pone.0125164.t002
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Table 3. Baseline characteristics of patients with stable CAD and atrial fibrillation by antithrombotic therapy.
Parameter Subgroup OAC alone or with antiplatelet
(n = 1051)
At least 1 antiplatelet
(n = 1178)
p value
Age, mean (SD), yearsa 71.7 (8.2) 68.6 (9.5) <0.001
Men, n (%)a 847 (80.8) 913 (77.5) 0.055
BMI, median (IQR), kg/m2 b 28.1 (25.3–31.4) 27.6 (25.0–30.5) 0.0039
Waist circumference, median (IQR), cmc 100 (92–109) 99 (90–106) <0.001
Education level, n (%) 0.004
Primary school or less 328 (31.2) 310 (26.3)
Secondary school 471 (44.8) 520 (44.1)
College or university 252 (24.0) 348 (29.5)
Time since 1st CAD, median (IQR), years 9 (4–14) 7 (3–12) <0.001
Medical history, n (%)
Myocardial infarctiond 525 (50.0) 591 (50.2) 0.94
PCI 472 (44.9) 587 (49.8) 0.020
CABGe 392 (37.3) 390 (33.1) 0.038
Internal cardiac deﬁbrillator 55 (5.2) 28 (2.4) <0.001
Pacemaker 154 (14.7) 106 (9.0) <0.001
Hospitalization for heart failure 187 (17.8) 127 (10.8) <0.001
Stroke 129 (12.3) 68 (5.8) <0.001
Permanent AFf 497 (58.5) 256 (26.6) <0.001
Asthma/COPD 126 (12.0) 149 (12.6) 0.64
Treated hypertension 824 (78.4) 921 (78.2) 0.90
Diabetesd 309 (29.4) 304 (25.8) 0.056
Dyslipidaemia 775 (73.7) 925 (78.5) 0.0081
Peripheral artery disease 191 (18.2) 157 (13.3) 0.0017
Angina and CCS class, n (%) <0.001
No angina 877 (83.4) 850 (72.2)
Class I 50 (4.8) 65 (5.5)
Class II 97 (9.2) 191 (16.2)
Class III 24 (2.3) 70 (5.9)
Class IV 3 (0.3) 2 (0.2)
Creatinine concentration, median (IQR),
mmol/Lg
0.095 (0.08–0.12) 0.093 (0.08–0.11) 0.045
Haemoglobin, median (IQR), mmol/Lh 8.6 (8.0–9.3) 8.7 (8.1–9.3) 0.31
Heart rate (electrocardiogram), mean (SD),
beats/mini
70.9 (14.2) 68.0 (13.0) <0.001
Heart rate (palpation), mean (SD), beats/
minj
70.1 (12.7) 68.2 (11.4) <0.001
SBP, mean (SD), mmHga 130.0 (16.2) 132.2 (16.2) 0.0011
DBP, mean (SD), mmHga 76.3 (9.7) 77.1 (10.4) 0.051
Left ventricular ejection fraction, mean
(SD), (%)k
52.2 (12.6) 56.2 (11.5) <0.001
Vessel disease, n (%)l 0.050
0 48 (5.4) 40 (4.1)
1 266 (30.2) 343 (35.0)
2 567 (64.4) 597 (60.9)
Baseline medications, n (%)
Aspirin 418 (39.8) 1064 (90.3) <0.001
Thienopyridinem 83 (7.9) 259 (22.0) <0.001
(Continued)
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Table 3. (Continued)
Parameter Subgroup OAC alone or with antiplatelet
(n = 1051)
At least 1 antiplatelet
(n = 1178)
p value
Other antiplateletd 43 (4.1) 110 (9.3) <0.001
Beta-blocker 797 (75.8) 895 (76.0) 0.94
Ivabradine 32 (3.0) 96 (8.1) <0.001
Calcium antagonist 282 (26.8) 365 (31.0) 0.03
Verapamil or diltiazem 76 (7.2) 68 (5.8) 0.16
ACE inhibitors 575 (54.7) 614 (52.1) 0.22
Angiotensin II receptor blocker 321 (30.5) 326 (27.7) 0.14
Lipid-lowering drug 914 (87.0) 1065 (90.4) 0.01
Long-acting nitrate 221 (21.0) 283 (24.0) 0.09
Other antianginal agente 111 (10.6) 198 (16.8) <0.001
Trimetazidinee 68 (6.5) 152 (12.9) <0.001
Diureticd 607 (57.8) 506 (43.0) <0.001
Other antihypertensive drugd 110 (10.5) 104 (8.8) 0.19
Digoxin and derivative 247 (23.5) 97 (8.2) <0.001
Amiodarone/dronedaroned 175 (16.7) 223 (18.9) 0.16
Other antiarrhythmic 38 (3.6) 70 (5.9) 0.01
Non-steroidal anti-
inﬂammatory druge
44 (4.2) 61 (5.2) 0.27
Anti-diabetes drug 262 (24.9) 254 (21.6) 0.06
CHA2DS2-VASc score, median (IQR)
b 4 (3–5) 3 (2–4) <0.001
CHA2DS2-VASc score, n (%)
b
0/1/2 214 (20.5) 355 (30.2) <0.001
3 261 (25.0) 317 (26.9)
4 233 (22.3) 257 (21.8)
5 184 (17.6) 159 (13.5)
6 154 (14.7) 89 (7.6)
HAS-BLED score, median (IQR)n 1 (1–2) 1 (1–1) <0.001
HAS-BLED score, n (%)n
<3 958 (91.6) 1153 (98.0) <0.001
3 88 (8.4) 23 (2.0)
ECG rhythm, n (%),f <0.001
Sinus rhythm 270 (31.8) 654 (67.9)
AF/ﬂutter 497 (58.5) 256 (26.6)
Paced rhythm 83 (9.8) 53 (5.5)
LBBB, n (%),o 85 (10.0) 70 (7.3) 0.035
Reimbursement of cardiovascular drugs,
n (%)b
<0.001
Full 525 (50.1) 464 (39.5)
Part 367 (35.1) 498 (42.3)
(Continued)
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Table 3. (Continued)
Parameter Subgroup OAC alone or with antiplatelet
(n = 1051)
At least 1 antiplatelet
(n = 1178)
p value
Not 155 (14.8) 214 (18.2)
Data missing for:
a3 patients (n = 2,226)
b6 patients (n = 2,223)
c29 patients (n = 2,200)
d1 patient (n = 2,228)
e2 patients (n = 2,227)
f416 patients (n = 1,813)
g499 patients (n = 1,730)
h689 patients (n = 1,540)
i414 patients (n = 1,815)
j4 patients (n = 2,225)
k581 patients (n = 1,648)
l368 patients (n = 1,861)
m5 patients (n = 2224)
n7 patients (n = 2,222)
o418 patients (n = 1,811).
Abbreviations: BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; DBP,
diastolic blood pressure; ECG, electrocardiogram; IQR, interquartile range; LBBB, left bundle branch block; OAC, oral anticoagulant therapy; SBP, systolic
blood pressure; SD, standard deviation.
doi:10.1371/journal.pone.0125164.t003
Fig 3. Antithrombotic therapy in patients with coronary artery disease and permanent or non-
permanent atrial fibrillation. Abbreviations: AF, atrial fibrillation; AP, antiplatelet; OAC, oral anticoagulant.
doi:10.1371/journal.pone.0125164.g003
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multivariable analysis, OAC use was independently associated with permanent AF, CHA2DS2-
VASc score, pacemaker therapy, stroke, absence of angina, decreased left ventricular ejection
fraction, increased waist circumference, and longer history of CAD (Fig 4). Conversely, history
of PCI, and no/partial reimbursement for cardiovascular medication were associated with re-
duced likelihood of OAC use. Perhaps surprisingly, multivessel disease, history of MI, and cor-
onary artery bypass graft surgery were not independently associated with likelihood of OAC
use. Overall, it seems that OAC is less likely to be prescribed in patients with stable CAD and
AF when CAD is considered the “primary” condition, as suggested by the lower use among pa-
tients with angina or previous PCI, whereas those with heart failure or permanent AF were
more likely to receive OAC therapy. OAC use was associated with higher HAS-BLED score,
probably because it is often a marker for greater CHA2DS2-VASc score, the two being correlat-
ed. It is also possible that many physicians were unaware of the HAS-BLED score at the time
the study was conducted. Antithrombotic treatment differed according to AF type, with parox-
ysmal and persistent AF being more frequent among patients not receiving OACs. This finding
is consistent with previous studies [16,17], and illustrates a gap between everyday clinical prac-
tice and the guideline recommendations to provide OAC to patients at risk irrespective of AF
type. The speciality of the physician taking care of the patients enrolled (general practitioner
Fig 4. Multivariable logistic regression results for odds of taking any oral anticoagulant therapy (either alone or with an antiplatelet) compared
with the antiplatelet alone group. Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; CI, confidence interval; CV, cardiovascular; OAC, oral
anticoagulant; PCI, percutaneous coronary intervention.
doi:10.1371/journal.pone.0125164.g004
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versus internist versus cardiologist) may also play a role in the use of OAC and/or antiplatelet
therapy in these patients.
Our results emphasize the fact that the individual patient’s thromboembolic risk should first
be considered, and their bleeding risk assessed thereafter, but clinicians frequently overestimate
bleeding risk [18–20]. All guidelines balance risk of stroke and bleeding. However, a high
bleeding risk is not per se a contraindication for OAC use and does not challenge our assump-
tion that most if not all patients with stable CAD and AF should be on OAC. Prevention of MI
and coronary events is an additional challenge in these patients [13]. Clinicians should proba-
bly focus more on the prevention of disabling—and potentially fatal—strokes and severe
bleeds, and place less emphasis on minor bleeding events. In the randomized ACTIVE-W trial
in patients with AF at risk of stroke, the occurrence of nonfatal strokes was associated with an
increased risk of subsequent mortality (hazard ratio 5.58, 95% confidence interval 3.84–8.10,
p<0.0001), whereas among the major bleeding events, only those also classified as severe in-
creased subsequent mortality (3.35, 2.12–5.27, p<0.0001) [21].
The addition of an antiplatelet agent to OAC should be considered in some subgroups with
CAD [22]. However, such combination therapy may present a challenge given the increased
risk of bleeding associated with these treatments [12]. Combined aspirin with clopidogrel is
less effective in preventing stroke than oral anticoagulation alone [23]. Dual antiplatelet thera-
py has been proposed as an initial option after stent implantation in AF patients at seemingly
low risk of thromboembolism in North American guidelines, but OAC alone should be pre-
scribed thereafter [24,25]. Physicians may, however, be reluctant to change antithrombotic
management once the patient is stable, which may explain why many patients received long-
term antiplatelet therapy in our analysis [26]. Of note, East Asia had guidelines with slightly
different thresholds and INR target for OAC use whilst the region contributed substantially to
the overall population. Removing East Asia and running a stepwise selection model on this
population as a sensitivity analysis provided results that were similar (data not shown).
In a consensus document on the optimal management of antithrombotic therapy in AF pa-
tients undergoing PCI/stenting, various antithrombotic strategies have been offered according
to the haemorrhagic risk and the clinical setting (elective or acute) [22]. At discharge from hos-
pital, triple antithrombotic therapy (oral anticoagulation, aspirin, and clopidogrel) is recom-
mended, ranging from2 weeks for elective procedures with high haemorrhagic risk up to 6
months for acute coronary syndrome procedures when the bleeding risk is low or intermediate.
According to the type of procedure, this regimen is then followed by OAC plus clopidogrel for
up to 12 months. Thereafter, warfarin alone is recommended lifelong, and this theoretically
should have been the strategy in a majority of our patients treated with PCI [1,22,24].
Current recommendations are based largely on limited evidence from small, single-centre,
and retrospectively analysed cohorts [27]. Thus there is a definite need for large-scale registries
that reflect patients treated in everyday practice, such as CLARIFY, and prospective clinical
studies to determine the optimal management of patients with AF and stable CAD. The devel-
opment of direct oral anticoagulants, which are more convenient to use and more effective
than warfarin in reducing the rates of stroke and systemic embolism with similar rates of major
haemorrhage, may be promising for patients with CAD and AF [28,29]. They may improve ad-
herence to guidelines, although further (randomized) studies are needed in this setting.
Limitations
This study is limited by its observational design. Given the diagnostic methods used with no
systematic ambulatory monitoring, the prevalence of paroxysmal AF may have been underesti-
mated, but use of OAC is likely to be even lower in these patients with undiagnosed AF.
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Although we adjusted for several variables, residual confounding, including variables related to
the severity of CAD, may account for some of the observed differences between patients treated
with OAC or with antiplatelet therapy. The lack of information on the percentage of patients
who had stents implanted and the proportion of bare-metal versus drug-eluting stents repre-
sents an issue, as this might have substantially impacted on the prescription as well as duration
of antithrombotic therapies, especially of antiplatelets. We did not perform an analysis evaluat-
ing whether patients received the same antithrombotic drug during the entire follow-up period
or for how long they received it. Nor did we retrieve information on how OAC was monitored
or about the quality of anticoagulation control for warfarin. Investigators were free to select the
antithrombotic treatments, and such choices are influenced by patient and lesion characteris-
tics: it may be that patients/lesions presumed to be at higher risk of stent thrombosis were pref-
erably treated by antiplatelet therapy to reduce this risk, even in so-called stable CAD after 12
months. Similarly, the expected risk of bleeding may have influenced the type of antithrombo-
tic treatment prescribed, although this does not clearly appear in our multivariable analysis.
The lack of use of OAC therefore represents a missed opportunity to prevent an adverse event
in patients with AF, but it is possible that operators succeed in equalizing risks and benefits in
different patients with CAD and AF by adequate selection of PCI with or without stenting and
antithrombotic treatment among different patient groups.
Conclusion
In this contemporary international cohort of patients with stable CAD and AF, most of whom
are theoretical candidates for anticoagulation, OACs were used in a minority, indicating a gap
between guidelines for AF and everyday clinical practice.
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